Updated:
CCRM Fertility
CCRM Fertility, founded by Dr. William Schoolcraft, operates a PE-backed network of fertility clinics known for lab protocols and live-birth rates.
CCRM Fertility
CCRM Fertility was founded in 2007 by Dr. William Schoolcraft, a reproductive endocrinologist who had spent two decades building the Colorado Center for Reproductive Medicine into a clinical outlier known for its proprietary blastocyst culture media and rigorous single-embryo transfer protocols. The firm's laboratory standards, developed through Schoolcraft's research, underpin its brand as a high-science fertility provider rather than a commoditized chain. The network operates 11 full-service clinics and multiple satellite locations across the United States and Canada, offering the full arc of fertility services — in vitro fertilization, genetic testing, egg freezing, and third-party reproduction — delivered through an integrated lab-physician model where embryologists and clinicians work under shared quality benchmarks. Its strategy combines de novo clinic openings with selective acquisitions of established practices that adopt CCRM's lab protocols. In 2021, TA Associates acquired a majority stake to accelerate this expansion, moving the firm from a founder-run practice to an institutionally backed platform. As of 2024, the company operates across four primary markets — Denver, Toronto, Los Angeles, and Stamford — with plans for further national density. CCRM's physician partnership structure retains Schoolcraft as medical director while recruiting high-volume doctors who receive equity participation. This tripartite structure — PE sponsor, founder legacy, and local physician-partners — is rare in fertility roll-ups, which more commonly centralize management at the corporate level. CCRM's structural differentiator is its laboratory-first identity in a sector where clinics typically compete on patient experience. Its labs in each hub operate on unified, internally developed media and growth systems, creating a franchise standard that is difficult for competitors to replicate without rebuilding their embryology workflow. This clinical IP, rather than a generic roll-up thesis, forms the backbone of the TA Associates investment.
General information
Firm type
Asset Manager
Year founded
2007
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Lone Tree
Corporate office
Lone Tree, CO, United States
Additional offices
Toronto, Canada · Los Angeles, CA · Stamford, CT
Principals
William Schoolcraft
Founder and Medical Director
Sector focus
Frequently asked questions
Who holds the investment decision-making authority at CCRM Fertility?
Strategic and capital allocation decisions sit with the board, led by majority investor TA Associates since their 2021 acquisition. Clinical and laboratory standards remain under Dr. William Schoolcraft's purview as medical director, while day-to-day operational leadership is executed by a CEO and a regional management structure. This creates a dual authority: TA Associates controls the growth strategy and M&A, while Schoolcraft oversees the core clinical IP.
How has the capital structure changed since TA Associates invested?
TA Associates acquired a majority interest in CCRM in 2021, transitioning the firm from a physician-owned partnership to an institutionally backed platform. Dr. Schoolcraft and other partner physicians retained significant minority equity, aligning their interests with the sponsor's hold period. The transaction provided a liquidity event for founding partners while capitalizing further de novo clinic builds and tuck-in acquisitions.
What is CCRM's acquisition strategy?
CCRM pursues a two-pronged expansion: building wholly owned, ground-up clinics especially in high-barrier urban markets like Toronto's Yorkville, and selectively acquiring existing fertility practices where physician-leaders agree to adopt CCRM's proprietary lab protocols. The firm does not operate a loose franchise model — every location eventually migrates to CCRM's central lab quality system and single-embryo transfer guidelines.
How does CCRM's lab model differ from other fertility clinic networks?
CCRM's core intellectual property lies in its embryology lab protocols, including a proprietary blastocyst culture medium and refined cryopreservation techniques developed by Dr. Schoolcraft's team. Unlike chains that acquire clinics and leave local labs intact, CCRM requires each hub to run on its standardized laboratory operating procedures and quality benchmarks, an integration path that limits acquisition targets but aims to preserve outcome consistency.
Is CCRM involved in fertility-related digital health or benefits platforms?
CCRM's model is anchored in brick-and-mortar labs and in-person clinical visits, with satellite offices offering telehealth for initial consultations. In 2023 it expanded its employer benefits partnerships to serve as a designated in-network provider for large self-insured employers through Progyny and similar platforms. However, it has not launched a standalone digital health app, distinguishing it from benefits-only fertility players.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: